Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Kirk Look
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(147)
•••
Comment by lonc17on Mar 31, 2024 11:24am
102 Views
Post# 35961672

RE:RE:Kirk Look

RE:RE:Kirk LookThanks 2020.

Here is the full accounting, as per SEDI. See the OPTIONS section. 

Insider name: Look, Kirk  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Common Shares  
        2173683 2012-11-09 2012-11-20 Direct Ownership : 00 - Opening Balance-Initial SEDI Report       26,400                
   
    O   2375880 2013-12-05 2013-12-09 Direct Ownership : 51 - Exercise of options +2,300 1.8080     28,700              
   
    A   2375880 2013-12-05 2013-12-09 Direct Ownership : 51 - Exercise of options +2,300 1.6500   28,700 28,700              
   
        2590621 2015-01-09 2015-01-09 Direct Ownership : 10 - Acquisition or disposition in the public market +10,000 0.5200 USD 38,700 38,700              
   
        3268747 2018-05-22 2018-11-23 Direct Ownership : 37 - Stock split or consolidation -34,627     4,073 4,073              
   
        3279425 2018-12-11 2018-12-12 Direct Ownership : 10 - Acquisition or disposition in the public market +4,100 2.7500   8,173 8,173              
   
        3286855 2018-12-21 2018-12-22 Direct Ownership : 10 - Acquisition or disposition in the public market +1,250 2.4060   9,423 9,423              
   
        3384949 2019-06-18 2019-06-18 Direct Ownership : 10 - Acquisition or disposition in the public market +1,500 2.2470   10,923 10,923              
   
        3704630 2021-03-12 2021-03-12 Direct Ownership : 57 - Exercise of rights +22,105     33,028 33,028              
   
        3961470 2022-06-14 2022-06-14 Direct Ownership : 10 - Acquisition or disposition in the public market +6,000 0.8600 USD 39,028 39,028              
   
        3962245 2022-06-15 2022-06-16 Direct Ownership : 10 - Acquisition or disposition in the public market +6,000 0.8900 USD 45,028 45,028              
   
Security designation: Options (Common Shares)  
        2170706 2012-11-09 2012-11-13 Direct Ownership : 00 - Opening Balance-Initial SEDI Report       158,700         Common Shares   158,700  
   
        2173686 2012-11-13 2012-11-20 Direct Ownership : 50 - Grant of options +200,000     358,700   2.0000   2022-11-13 Common Shares +200,000 358,700  
   
        2190473 2012-12-17 2012-12-18 Direct Ownership : 50 - Grant of options +40,000     398,700 398,700 4.2100   2022-12-17 Common Shares +40,000 398,700  
   
    O   2375810 2013-12-04 2013-12-09 Direct Ownership : 51 - Exercise of options -35,000       363,700 1.6500   2013-12-04 Common Shares -35,000    
   
    A   2375810 2013-12-04 2013-12-09 Direct Ownership : 51 - Exercise of options -35,000     363,700 363,700 1.6500   2013-12-05 Common Shares -35,000 363,700  
   
    O   2375815 2013-12-05 2013-12-09 Direct Ownership : 52 - Expiration of options -10,000       353,700 1.6500   2013-12-05 Common Shares -10,000    
   
    A   2375815 2013-12-05 2013-12-09 Direct Ownership : 51 - Exercise of options -10,000     353,700 353,700 1.6500   2013-12-05 Common Shares -10,000 353,700  
   
        2380039 2013-12-11 2013-12-16 Direct Ownership : 50 - Grant of options +160,000 1.7400   513,700 513,700     2023-12-11 Common Shares +160,000 513,700  
   
        2480406 2014-05-28 2014-05-28 Direct Ownership : 52 - Expiration of options -15,000 8.1000   498,700 498,700     2014-05-28 Common Shares -15,000 498,700  
   
        2574869 2014-12-09 2014-12-12 Direct Ownership : 52 - Expiration of options -15,000 5.0000   483,700 483,700     2014-12-09 Common Shares -15,000 483,700  
   
        2747843 2015-12-01 2015-12-02 Direct Ownership : 50 - Grant of options +464,000 0.4200   947,700 947,700     2025-12-01 Common Shares +464,000 947,700  
   
        2945528 2017-01-16 2017-01-19 Direct Ownership : 50 - Grant of options +300,000 0.2800   1,247,700 1,247,700     2027-01-16 Common Shares +300,000 1,247,700  
   
        2945531 2017-01-18 2017-01-19 Direct Ownership : 52 - Expiration of options -4,700 2.2500   1,243,000 1,243,000     2017-01-18 Common Shares -4,700 1,243,000  
   
        3098039 2017-12-12 2017-12-13 Direct Ownership : 52 - Expiration of options -9,000 2.2200   1,234,000 1,234,000     2017-12-12 Common Shares -9,000 1,234,000  
   
Security designation: Rights Performance Share Units (Common Shares)  
        2945627 2012-11-09 2017-01-19 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
    A   2889992 2016-09-09 2017-01-19 Direct Ownership : 56 - Grant of rights +210,000     210,000 210,000       Common Shares +210,000 210,000  
   
        3268748 2018-05-22 2018-11-23 Direct Ownership : 37 - Stock split or consolidation -187,895     22,105 22,105       Common Shares -187,895 22,105  
   
        3704626 2021-03-12 2021-03-12 Direct Ownership : 57 - Exercise of rights -22,105     0 0       Common Shares -22,105 0  
   
Security designation: Rights Restricted Share Units (Common Shares)  
        2889991 2012-11-09 2016-09-13 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
    O   2889992 2016-09-09 2016-09-13 Direct Ownership : 56 - Grant of rights +210,000               Common Shares +210,000    
   
        4171333 2023-08-15 2023-08-18 Direct Ownership : 56 - Grant of rights +28,200     28,200 28,200       Common Shares +28,200 28,200  
   

        4224367 2023-12-08 2023-12-13 Direct Ownership : 56 - Grant of rights +62,100     90,300 90,300

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities